Design and development of novel, potent and brain penetrant cyclic LRRK2 inhibitors for the treatment of Parkinson's disease.
Parkinson's disease (PD) is a debilitating and progressive neurodegenerative disorder, where disease-modifying therapy (DMT) represents a major unmet clinical need. Advances in the understanding of underlying pathogenesis reveal the potential therapeutic value of inhibitors targeting leucine-rich repeat kinase 2 (LRRK2...